Business
Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"– Highlight of accepted abstracts includes new real-world data on lipid-lowering therapy usage, submitted in partnership with UT Southwestern – – Accepted abstracts showcase breadth of Esperion’s research into efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and a variety of comorbid metabolic conditions – ANN ARBOR, Mich., May 31, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced five abstracts have been accepted for presentation at the National Lipid Association Scientific Sessions (NLA 2022 Scientific Sessions) being held in-person in Scottsdale, Arizona. “In the wake of the pandemic, the US is in serious risk of moving backward on critical public health initiatives like maintaining a healthy cholesterol and metabolic profile. We believe Esperion is uniquely positioned to help address this issue with our approved therapies,” said Sheldon Koenig, president and chief executive officer of Esperion. “That is one reason we are presenting our real-world analysis on the major gaps in cardiovascular and metabolic care in advance of readouts from our upcoming pivotal CLEAR Outcomes study.” Expert Theatre Title: Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C Date & Time: 6/4/2022, 8:00 – 8:50 AM Speaker:William Cromwell, MD, FAHA, FNLA E-Poster Presentations Title: Safety and efficacy of bempedoic acid in patients with renal impairment* Abstract #: 32 Date & Time:6/3/2022, 11:25-11:42 AM Authors: Presented on behalf of all authors by Peter Toth, MD, PhD, FCCP, FAHA, FESC, FACC Title: Efficacy and safety of bempedoic acid in patients with metabolic syndrome* Abstract #: 34 Date & Time:6/3/2022, 11:48 AM-12:05 PM Authors:Presented on behalf of all authors by Michael Shapiro, DO, MCR, FACC, FNLA Title: Pharmacokinetics, pharmacodynamics, and safety of bempedoic acid in a Phase 1 clinical trial in healthy Japanese, Chinese and White subjects* Abstract #:35 Date & Time:6/3/2022, 11:48 AM-12:05 PM Authors: Presented on behalf of all authors by Benny Amore, PhD Title:Lipid-Lowering Therapy for Primary Prevention of Cardiovascular Disease: A Nationwide Analysis of 440,721 Patients Abstract #:73 Date & Time:6/3/2022, 11:48 AM-12:05 PM Authors:Presented on behalf of all authors by Ahmed Kolkailah, MD, MSc Title:Safety and efficacy of bempedoic acid in patients with hypertension* Abs...